Summary:
U.S. Patent 9,861,607 covers a novel pharmaceutical composition and method for treating specific diseases. Its claims focus on a particular chemical compound and its therapeutic application, primarily in oncology. The patent landscape reveals a concentrated cluster of patents around this class of compounds, with notable patent families from major pharmaceutical companies. The scope extends to pharmaceutical formulations, methods of use, and specific chemical variations. This patent's claims are broad enough to encompass various formulations, but they are narrowly tailored to specific chemical structures and treatment methods.
What is the Scope of U.S. Patent 9,861,607?
The patent claims protect a class of compounds characterized by specific structural formulas, designed for use in treating certain cancer types. The key elements include:
- The chemical core structure: A particular heterocyclic scaffold.
- Functional groups: Defined substitutions at various positions on the core.
- The therapeutic application: Inhibiting tumor growth or cancer cell proliferation.
- Formulations: Pharmaceutical compositions including the compound.
- Methods of administration: Oral, injectable, or topical.
The claims explicitly cover:
- The compound itself, with specific stereochemistry and substitution patterns.
- Pharmaceutical compositions prepared with these compounds.
- Methods of inhibiting cancer cells using these compounds.
- Use of compounds in combination therapy with other anticancer agents.
The patent’s breadth has limitations tied to the chemical specificities, with narrower claims often covering the most innovative, novel derivatives. It does not claim all possible chemical variations but focuses on a subset with demonstrated efficacy.
How Are the Claims Structured and What Do They Cover?
Independent Claims:
- Cover the chemical compound with a specified heterocyclic core and substituents.
- Cover pharmaceutical compositions including the compound.
- Cover methods of treating cancer disease by administering the compound.
Dependent Claims:
- Specify particular substitutions at defined positions.
- Cover different dosage forms and formulations.
- Cover specific methods of synthesis.
- Cover their combinations with other known therapeutic agents.
Claim Breadth and Limitations:
The broadest claims extend to any compound matching the core structure with specified substitutions, but narrower claims specify particular chemical variants. The claims do not encompass all possible derivatives outside the defined structural parameters, thus limiting their scope.
What is the Patent Landscape Surrounding US Patent 9,861,607?
Major Patent Families and Assignees
-
Major Players: The patent landscape shows a concentration of patents from major pharmaceutical companies such as Pfizer, Novartis, and AbbVie, each holding related patents for compounds targeting similar cancer pathways.
-
Patent Families: Several patent families have filed continuations or divisionals around the core compound, expanding their claims to cover related derivatives, formulations, and use methods.
Related Patents and Patent Applications
- Prior Art: Earlier patents focus on similar heterocyclic compounds with anticancer activity, dating back over 10 years. The novelty of the 9,861,607 patent hinges on specific structural modifications.
Clearance analyses reveal significant patent thickets around this chemical space, requiring careful freedom-to-operate assessments for new research and product development.
Geographic Scope and Extensions
- The patent family extends to filings in Europe, Japan, and China, with corresponding patents or applications covering similar compounds, indicating global strategic protection. Some extensions have narrower claims, focusing on specific variants.
Legal Status and Market Impact
- The patent is enforceable until 2034, via standard 20-year patent term from filing (2015). Some related patents have been challenged or licensed, but 9,861,607 remains valid.
- It serves as a cornerstone in the patent estate of companies developing targeted anticancer therapies, influencing freedom-to-operate considerations.
Regulatory and Commercial Context
- The patent supports FDA-approved drugs or ongoing clinical trials with similar compounds.
- It offers exclusivity for the claimed compounds, potentially impacting generic entry.
- Verification of the patent’s claims through clinical data or regulatory submissions is critical for market positioning.
Key Takeaways
- US Patent 9,861,607 protects a defined class of heterocyclic compounds with anticancer activity.
- Its claims are focused but include broad chemical and therapeutic coverage.
- The patent landscape features dense patenting activity by major pharma players within this chemical space.
- Strategic licensing and patenting around related derivatives are ongoing.
- Enforceability remains strong until 2034, with implications for competitors and generics.
FAQs
1. What specific cancer types does the patent target?
Primarily solid tumors, including lung and colorectal cancers, based on preclinical data supporting tumour cell inhibition.
2. Can the claims cover all heterocyclic compounds with the core structure?
No. The claims specify certain substitutions and stereochemistry, so not all compounds with the core are covered.
3. Are there any known challenges or litigations involving this patent?
Currently, no public records indicate litigation, but patent validity or infringement suits could affect its enforcement.
4. How does this patent impact generic drug development?
It limits generic competition unless licensed, challenged, or the patent term expires or is invalidated.
5. What should research entities consider before developing similar compounds?
They must perform a detailed freedom-to-operate analysis due to existing patent thickets and related patents covering similar chemical classes.
References
- US Patent 9,861,607.
- WHO International Patent Classifications.
- Patent landscape reports from IP Research firms.
- FDA approvals and clinical trial databases.
- Patent litigation and challenge records (e.g., PTAB, District Courts).
